New Drug Treatment For Multiple Sclerosis Raise Risk Of Colorectal Cancer
For the first time a new study suggests patients who use the New Multiple Sclerosis Drugmay be at greater risk for the colorectal cancer.Furthermore the study published in the journal Neurology supports previous research that the suggests the drug Treatment For Multiple Sclerosis increase the risk of the acute myeloid leukemia (AML). Mitoxantrone brand name Novantrone is a new drug Treatment For Multiple Sclerosis approved for the reduction of the disease relapses among patients with the aggressive multiple sclerosis (MS) who do not answer to other therapies.
This Drug Treatment For Multiple Sclerosis works by the suppressing the immune system reducing the activity of T cells, B cells, and macrophages that are believed to the promote the attack on myelin the protective coating that surrounds nerves. However Dr. Mathias Buttmann of the University of Würzburg or Germany and colleagues note that the use of mitoxantrone for MS is limited primarily because previous research has suggested New Drug Treatment For Multiple Sclerosis raises the risk of heart problems and AML.For this latest study the team further investigated the association between mitoxantrone and cancer.